Curated News
By: NewsRamp Editorial Staff
March 19, 2026
Soligenix CEO Touts Positive HyBryte™ Data, Eyes Transformational CTCL Milestone
TLDR
- Soligenix's strong Phase 3 FLASH2 study results for HyBryte could provide investors with a significant advantage through potential early study completion and upcoming commercialization opportunities.
- Soligenix is conducting a Phase 3 FLASH2 study for HyBryte, with an interim analysis showing blinded aggregate response rates above initial assumptions, guiding potential study completion or continued enrollment.
- Soligenix's HyBryte therapy for cutaneous T-cell lymphoma addresses an unmet medical need, potentially improving treatment outcomes and quality of life for patients with this rare disease.
- Soligenix's HyBryte uses synthetic hypericin in a novel photodynamic therapy with safe visible light, representing an innovative approach to treating cutaneous T-cell lymphoma.
Impact - Why it Matters
This news is significant for patients, investors, and the broader healthcare landscape. For individuals suffering from cutaneous T-cell lymphoma (CTCL), a rare and often debilitating cancer, HyBryte™ represents a promising new therapeutic option that utilizes visible light, potentially offering a safer and more targeted treatment compared to existing modalities. Positive Phase 3 data could accelerate its path to market, addressing a critical unmet medical need. For investors and the biopharmaceutical industry, strong interim results could validate Soligenix's technology platform, enhance its valuation, and attract partnership or acquisition interest, fueling further research and development. Success here also reinforces the viability of photodynamic therapy and specialized approaches for rare diseases, encouraging innovation in a challenging sector. Furthermore, the company's parallel work on public health vaccines, supported by government agencies, highlights its role in broader pandemic and biodefense preparedness, making its overall progress a barometer for biotech resilience and strategic focus.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, was featured in the latest BioMedWire Podcast, where CEO Christopher Schaber provided an optimistic update on the company's flagship product. The discussion centered on the upcoming interim analysis of the Phase 3 FLASH2 study evaluating HyBryte™ (SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare cancer. Schaber highlighted that blinded aggregate response rates from the ongoing trial are running above the company's initial assumptions, setting the stage for potential positive outcomes that could include early study completion or continued enrollment. He emphasized that the upcoming interim and subsequent top-line data represent potentially transformational milestones that could significantly bolster the drug's path toward regulatory approval, commercialization, and strategic partnership opportunities.
Soligenix's Specialized BioTherapeutics segment is focused on bringing HyBryte™ to market as a novel photodynamic therapy utilizing safe visible light for CTCL. Beyond this lead candidate, the company's pipeline includes expanding synthetic hypericin (SGX302) into psoriasis, developing innate defense regulator technology like dusquetide (SGX942) for inflammatory diseases such as oral mucositis, and exploring (SGX945) for Behçet’s Disease. The company also maintains a Public Health Solutions business segment, supported by government funding, which is advancing vaccine candidates including RiVax® for ricin toxin, vaccines for filoviruses like Marburg and Ebola, and CiVax™ for COVID-19, utilizing its proprietary ThermoVax® heat stabilization platform. For more details, investors can view the full press release.
The news was disseminated through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio of IBN (InvestorBrandNetwork), which focuses on the biotechnology and life sciences sectors. BMW provides a suite of services including wire distribution, article syndication to over 5,000 outlets, press release enhancement, and social media distribution via IBN to reach a broad audience of investors and the general public. This platform ensures that updates from companies like Soligenix gain significant visibility and brand awareness in a crowded information landscape. For ongoing updates, the company's newsroom is available, and to receive SMS alerts from BioMedWire, individuals can text "Biotech" to 888-902-4192.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix CEO Touts Positive HyBryte™ Data, Eyes Transformational CTCL Milestone
